安国际医学投资股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：西安国际医学投资股份有限公司 | | --- | | AND THE WATER SEP P LACE I THE | 单位:万元 | 非经营性资金 | 资金吉用方名称 | 占用方与上市公司 | 上市公司核算 | 2025 年初占用资金 | 2025 年未年度早 用累计发生金额 | 2025年半年度 占用资金的利息 | 2025 年半年度 | 2025 年半年度末 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关系 | 的会计科目 | 余额 | | | 偿还累计发生额 | 占用资金余额 | | | | | O | | | | (不含利息) | (如有) | | | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 计 11 | 124 2 | | | | | | | | | | | | 116 | | | | | | | ...

截至8月20日收盘，高压氧舱概念下跌0.68%，位居概念板块跌幅榜前列，板块内，创新医疗、盈康生 命、澳洋健康等跌幅居前，股价上涨的有7只，涨幅居前的有铁建重工、三星医疗、大湖股份等，分别 上涨4.29%、1.08%、0.89%。 今日涨跌幅居前的概念板块 资金面上看，今日高压氧舱概念板块获主力资金净流出4.44亿元，其中，6股获主力资金净流出，净流 出资金居首的是创新医疗，今日主力资金净流出5.37亿元，净流出资金居前的还有澳洋健康、大湖股 份、盈康生命等，主力资金分别净流出2254.11万元、1602.40万元、1020.68万元。今日主力资金净流入 居前的概念股有铁建重工、三星医疗、金陵药业等，主力资金分别净流入1.32亿元、1593.32万元、 553.33万元。（数据宝） 高压氧舱概念资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002173 | 创新医疗 | -7.21 | 30.17 | -53654.51 | | 002172 | 澳洋健康 | -0.23 | 5.1 ...

金融界消息 截至2025年8月19日收盘，国际医学（000516）报收于5.44元，上涨0.18%，换手率1.78%， 成交量39.33万手，成交金额2.15亿元。 资金流向方面，今日主力资金净流入1115.57万元，占比成交额5.19%。其中，超大单净流入601.59万 元、占成交额2.8%，大单净流入513.98万元、占成交额2.39%，中单净流出流出1759.65万元、占成交额 8.18%，小单净流入644.09万元、占成交额3.0%。 国际医学最新一期业绩显示，截至2025一季报，公司营业总收入9.97亿元、同比减少14.99%，归属净利 润10635.39万元，同比减少1.37%，扣非净利润11974.67万元，同比减少33.27%，流动比率0.333、速动 比率0.318、资产负债率67.64%。 天眼查商业履历信息显示，西安国际医学投资股份有限公司，成立于1996年，位于西安市，是一家以从 事卫生为主的企业。企业注册资本225820.1153万人民币。公司法定代表人为史今。 来源：金融界 通过天眼查大数据分析，西安国际医学投资股份有限公司共对外投资了43家企业，知识产权方面有商标 信息2条，此外 ...

Core Viewpoint - The Jinan International Medical Center is actively facilitating communication between medical device companies and regulatory bodies to streamline the registration process for medical devices [1][3]. Group 1: Event Overview - The Jinan International Medical Center organized a special guidance consultation activity for six medical device companies at the Shandong Provincial Food and Drug Review and Inspection Center [1]. - Following the initial consultation, some companies engaged in discussions regarding product testing technical issues at the Shandong Provincial Medical Device and Drug Packaging Inspection Research Institute [1]. Group 2: Expert Guidance - Experts from the Shandong Provincial Food and Drug Review and Inspection Center provided detailed guidance on key and challenging issues in the medical device registration process [3]. - Company representatives raised specific questions related to registration documentation, product technical requirements, clinical trials, and verification processes, which were addressed by the experts with practical suggestions [3]. Group 3: Impact on Companies - The face-to-face communication helped companies resolve many registration-related confusions and deepened their understanding of relevant policies, regulations, and review requirements [3]. - The Medical Center's committee is committed to optimizing the business environment in the region by providing precise and personalized services to enterprises [3]. Group 4: Regulatory Support - The Provincial Drug Administration has established a "review and inspection linkage" service channel to enhance support for innovative device applications [3]. - The organization of this special guidance consultation activity exemplifies the committee's commitment to providing precise services to companies, effectively shortening the registration process and boosting the development vitality of medical device enterprises in the region [3].

融券方面，当日融券卖出0.00万股，净卖出0.00万股。 来源：金融界 8月13日，沪深两融数据显示，国际医学获融资买入额0.22亿元，居两市第1866位，当日融资偿还额0.23 亿元，净卖出58.71万元。 最近三个交易日，11日-13日，国际医学分别获融资买入0.11亿元、0.18亿元、0.22亿元。 ...

天眼查商业履历信息显示，西安国际医学投资股份有限公司，成立于1996年，位于西安市，是一家以从 事卫生为主的企业。企业注册资本225820.1153万人民币。公司法定代表人为史今。 通过天眼查大数据分析，西安国际医学投资股份有限公司共对外投资了43家企业，知识产权方面有商标 信息2条，此外企业还拥有行政许可26个。 来源：金融界 金融界消息 截至2025年8月13日收盘，国际医学（000516）报收于5.41元，下跌0.73%，换手率1.41%， 成交量31.11万手，成交金额1.68亿元。 资金流向方面，今日主力资金净流出1403.56万元，占比成交额8.34%。其中，超大单净流出1538.41万 元、占成交额9.14%，大单净流入134.85万元、占成交额0.8%，中单净流出流入783.81万元、占成交额 4.66%，小单净流入619.75万元、占成交额3.68%。 国际医学最新一期业绩显示，截至2025一季报，公司营业总收入9.97亿元、同比减少14.99%，归属净利 润10635.39万元，同比减少1.37%，扣非净利润11974.67万元，同比减少33.27%，流动比率0.333、速动 比率0.31 ...

证券之星消息，8月13日医疗服务板块较上一交易日上涨4.02%，创新医疗领涨。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流入19.62亿元，游资资金净流出7449.63万元，散户资 金净流出18.88亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | = 11.30 乙 | 11.46% | -1.00 Z | -1.02% | -10.30 Z | -10.45% | | 300759 康龙化成 | | 2.48亿 | 9.09% | 4825.42万 | 1.77% | -2.96 Z | - ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of International Medicine (000516) as of August 11, 2025, with a closing price of 5.41 yuan, reflecting a 0.74% increase [1] - The company reported a total operating revenue of 999.7 million yuan for Q1 2025, representing a year-on-year decrease of 14.99%, and a net profit attributable to shareholders of 106.35 million yuan, down 1.37% year-on-year [1] - The company's liquidity ratios are low, with a current ratio of 0.333 and a quick ratio of 0.318, alongside a high debt-to-asset ratio of 67.64% [1] Group 2 - The stock experienced a net outflow of 13.25 million yuan in principal funds, accounting for 7.93% of the total transaction amount, with significant outflows from large orders [1] - International Medicine has invested in 43 external enterprises and holds 2 trademark registrations, along with 26 administrative licenses [2]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 其中，年薪排行前三的董秘分别为康龙化成的Gilbert Shing Chung Li（李承宗）、昭衍新药的高大鹏、 凯莱英的徐向科，三人年薪分别为198.55万元、173.84万元、161.14万元。 从薪酬变动幅度看，海特生物的杨坤2024年薪酬降幅最大，同比降幅达78.96%；何氏眼科的周晋峰薪 酬增幅最大，同比涨幅达142.8%。 责任编辑：公司观察 从董秘的年龄分布来看，40岁及以下的董秘是市场的中坚力量，占比共计达到43%；50岁以上的董秘占 比为22%；40岁-50岁的董秘群体占比为35%。其中，目前仍任职的最年轻的男上市公司董秘年龄32岁， 为盈康生命的刘泽霖；最年轻的女董秘年龄为32岁，为创新医疗的郭立丹。 从董秘的学历分布看，拥有本科、硕士、博士学历的董秘占比分别为34%、52%、14%，其中，获得博 士学历的董秘共7人，分别为新里程的徐旭、药石科技的余善宝、华厦眼科的曹乃恩、爱尔眼科的吴士 君、国际医学的丁震、和元生物的徐鲁媛、诺思格的李树奇。其中，华厦眼科的曹乃恩为行业唯一一个 拥有博士学历的专职董秘。 从 ...

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]